Tego Science, Inc. Logo

Tego Science, Inc.

Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.

191420 | KO

Overview

Corporate Details

ISIN(s):
KR7191420009
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tego Science, Inc. is a biopharmaceutical company specializing in advanced regenerative medicine, leveraging proprietary cell culture technology. Founded in 2001, the company develops, manufactures, and commercializes cell therapies for skin regeneration and wound healing. Its key approved products include Holoderm® for severe burns, Kaloderm® for diabetic foot ulcers, and Rosmir® for wrinkle improvement. Beyond therapeutics, Tego Science offers Neoderm®, a 3D cultured skin model as an alternative to animal testing, and provides Contract Development and Manufacturing Organization (CDMO) services from its GMP facility. The company maintains a robust R&D pipeline, with candidates like TPX-115 for rotator cuff tears, and operates a globally compliant allogeneic cell bank to ensure stable production of its innovative treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-27 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-05-26 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 111.0 KB
2025-05-23 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 108.1 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.1 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-19 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.2 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 134.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 138.0 KB
2025-02-14 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-02-14 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (회전근개 부분층 파열 개선을 위한 동종피부유래섬유아세포(TPX-11…
Korean 10.2 KB
2025-01-31 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB

Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tego Science, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.